2013
DOI: 10.1021/jm401115g
|View full text |Cite
|
Sign up to set email alerts
|

Aurora Isoform Selectivity: Design and Synthesis of Imidazo[4,5-b]pyridine Derivatives as Highly Selective Inhibitors of Aurora-A Kinase in Cells

Abstract: Aurora-A differs from Aurora-B/C at three positions in the ATP-binding pocket (L215, T217, and R220). Exploiting these differences, crystal structures of ligand–Aurora protein interactions formed the basis of a design principle for imidazo[4,5-b]pyridine-derived Aurora-A-selective inhibitors. Guided by a computational modeling approach, appropriate C7-imidazo[4,5-b]pyridine derivatization led to the discovery of highly selective inhibitors, such as compound 28c, of Aurora-A over Aurora-B. In HCT116 human colon… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

1
36
0

Year Published

2014
2014
2022
2022

Publication Types

Select...
6
1

Relationship

2
5

Authors

Journals

citations
Cited by 71 publications
(37 citation statements)
references
References 47 publications
1
36
0
Order By: Relevance
“…Functionalized pyridoimidazoles remained difficult to synthesize, even with the development of C À H functionalization methods. [10] However, as shown in Scheme 3, pyridoimidazoles could easily be prepared through the electrolysis of 4and 3-aminopyridine-derived substrates. In particular, the products when using the latter (5 d-k) were formed with excellent regioselectivity (see the Supporting Information for…”
mentioning
confidence: 99%
“…Functionalized pyridoimidazoles remained difficult to synthesize, even with the development of C À H functionalization methods. [10] However, as shown in Scheme 3, pyridoimidazoles could easily be prepared through the electrolysis of 4and 3-aminopyridine-derived substrates. In particular, the products when using the latter (5 d-k) were formed with excellent regioselectivity (see the Supporting Information for…”
mentioning
confidence: 99%
“…Nevertheless, the rationale for selective Aurora isoform inhibition vs pan-Aurora inhibition remains unclear and the ideal inhibitor profile has yet to be established. 5,28 In Vivo Studies. Compound 47 was evaluated in different tumor models and showed significant efficacy in mice bearing the human acute myeloid leukemia EOL-1 and the human colon adenocarcinoma HCT116 xenografted subcutaneously (data not shown).…”
Section: Journal Of Medicinal Chemistrymentioning
confidence: 99%
“…Several Aurora kinase inhibitors have been identified as excellent antitumor inhibitors. Recently, it has been reported that a series of imidazo [4,5-b]pyridine derivatives possess excellent potencies as orally bioavailable Aurora A inhibitors [7,8].…”
Section: Introductionmentioning
confidence: 99%